5 Insightful Analyst Questions From Acadia Healthcare’s Q3 Earnings Call

Acadia Healthcare’s third quarter results were marked by a negative market reaction, as management pointed to ongoing Medicaid-related volume and reimbursement pressures. CEO Christopher Hunter cited softer-than-expected volumes in the company’s Medicaid book of business, especially in acute care, as a key factor. The company also faced rising employee health costs and increased professional and general liability expenses, leading to a notable reduction in operating margin. Management acknowledged these headwinds, describing the quarter’s performance as impacted by “incremental headwinds from rates and benefit expense related to employee health care costs.”

Acadia Healthcare (ACHC) Q3 CY2025 Highlights:

• Revenue: $851.6 million vs analyst estimates of $846 million (4.4% year-on-year growth, 0.7% beat)

• Adjusted EPS: $0.72 vs analyst estimates of $0.66 (9.1% beat)

• Adjusted EBITDA: $173 million vs analyst estimates of $178.4 million (20.3% margin, 3% miss)

• The company dropped its revenue guidance for the full year to $3.29 billion at the midpoint from $3.33 billion, a 1.1% decrease

• Management lowered its full-year Adjusted EPS guidance to $2.40 at the midpoint, a 5.9% decrease

• EBITDA guidance for the full year is $655 million at the midpoint, below analyst estimates of $683.3 million

• Operating Margin: 9%, down from 15.8% in the same quarter last year

• Sales Volumes rose 5.7% year on year (2.4% in the same quarter last year)

• Market Capitalization: $1.68 billion

While we enjoy listening to the management’s commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Acadia Healthcare’s Q3 Earnings Call

• Albert Rice (UBS) asked about the specifics of Medicaid payer friction. CEO Christopher Hunter explained that the greatest pressure was in markets with heavy Medicaid exposure, noting more frequent utilization reviews and denials impacting reimbursement and length of stay.

• Pito Chickering (Deutsche Bank) pressed management on the durability of headwinds like bad debt, denials, and liability expenses. CFO Todd Young responded that some costs are seasonal or one-time, with startup and closure costs expected to step down, but broader industry cost pressures are likely to persist.

• Brian Tanquilut (Jefferies) sought detail on how reduced capital expenditure aligns with ongoing bed additions. Hunter clarified that most spending for facilities opening next year occurred this year, and projects with insufficient returns were paused or canceled.

• Benjamin Mayo (Leerink Partners) questioned if paused de novo projects might be abandoned and how contractual obligations affect capital strategy. Hunter confirmed joint venture commitments would be honored, but non-essential projects could be exited if returns are not compelling.

• Ryan Langston (TD Cowen) inquired about the trajectory of legal expenses. Hunter said that legal costs peaked in the prior quarter and are expected to decline materially as related investigations wind down.